Compare Novo Nordisk A/S (NVO) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs PubMatic Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while PubMatic Inc trades at $13 (market cap $607.48M). The key difference: Novo Nordisk A/S is far larger — about 363× PubMatic Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| NVO | PUBM | |
|---|---|---|
Market Cap | $220.53B | $607.48M |
Sector | Health | Technology |
52-Week High | $71.70 | $13.83 |
52-Week Low | $35.29 | $6.28 |
Enterprise Value | $239.49B | $504.98M |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
